Obesity and allometric scaling of pharmacokinetics

Clinical Pharmacokinetics

Volumn 50, Issue 11, 2011, Pages 751-753

  Eleveld, Douglas J ^a   Proost, Johannes H ^a   Absalom, Anthony R ^a   Struys, Michel M R F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Body weight; Dose prediction; Obesity; Overweight; Pharmacokinetic modelling; Pharmacokinetics; Propofol

Indexed keywords

PROPOFOL;

ALLOMETRY; BODY COMPOSITION; BODY FAT; BODY MASS; BODY SIZE; BODY WEIGHT; DRUG CLEARANCE; DRUG DISTRIBUTION; HUMAN; LIFE EXPECTANCY; NOTE; OBESITY; PRIORITY JOURNAL;

ANESTHETICS, INTRAVENOUS; FEMALE; HUMANS; MALE; OBESITY, MORBID; PROPOFOL;

EID: 80053599805     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11594080-000000000-00000     Document Type: Note

References (15)

1. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49: 71-87
2. Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-32 (Pubitemid 351738156)
3. Peeters MYM, Allegaert K, Blussé Van Oud-Alblas HJ, et al. Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model. Clin Pharmacokinet 2010; 49: 269-75
4. Kleiber M. Body size and metabolism. Hilgardia 1932; 6: 315-51
5. Van Kralingen S, Diepstraten J, Peeters MYM, et al. Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients. Clinical Pharmacokinetics 2011; 50: 739-50
6. Cort́ nez LI, Anderson BJ, Penna A, et al. Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. Br J Anaesth 2010; 105: 448-56
7. Servin F, Farinotti R, Haberer JP, et al. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide: a clinical and pharmacokinetic study. Anesthesiology 1993; 78: 657-65 (Pubitemid 23110039)
8. Albertin A, Poli D, La Colla L, et al. Predictive performance of 'Servin's formula' during BIS-guided propofol-remifentanil target-controlled infusion in morbidly obese patients. Br J Anaesth 2007; 98: 66-75 (Pubitemid 44896753)
9. Ingrande J, Brodsky JB, Lemmens HJ. Lean body weight scalar for the anesthetic induction dose of propofol in morbidly obese subjects. Anesth Analg 2011; 113: 57-62
10. Van Kralingen S, Diepstraten J, Van de Garde EMW, et al. Comparative evaluation of propofol 350 and 200mgfor induction of anaesthesia inmorbidly obese patients: a randomized double-blind pilot study. Eur J Anaesthesiol 2010; 27: 572-4
11. La Colla L, Albertin A, La CollaG, et al. No adjustment vs adjustment formula as input weight for propofol target-controlled infusion in morbidly obese patients. Eur J Anaesthesiol 2009; 26: 362-9
12. La Colla L, Albertin A, La Colla G. Pharmacokinetic model-driven remifentanil administration in the morbidly obese: the 'critical weight' and the 'fictitious height', a possible solution to an unsolved problem? Clin Pharmacokinet 2009; 48: 397-8
13. Coetzee JF. Total intravenous anaesthesia to obese patients: largely guesswork? Eur J Anaesthesiol 2009; 26: 359-61
14. Ingrande J, Lemmens HJ. Dose adjustment of anaesthetics in the morbidly obese. Br J Anaesth 2010; 105 Suppl. 1: i16-23
15. Lemmens HJM. Perioperative pharmacology in morbid obesity. Curr Opin Anaesthesiol 2010; 23: 485-91